The Checkout: Coconut Bliss Launches New Line, CBD & Hemp Update – NOSH

Welcome to The Checkout: an express lane for weekly news you need to know, always 10 items or less.

Coconut Bliss Launches New, More Affordable Line ‘Everyday Bliss’

Luna & Larry’s Coconut Bliss is looking to bring sweet, smooth, dairy-free joy to more consumers with this week’s release of Everyday Bliss, the company’s first new line since launching in 2005. The products will be sampled next week at Natural Products Expo West.

“It’s very much a labor of love and a response to the feedback and needs of our current customers,” Kim Gibson Clark, Luna & Larry’s Coconut Bliss president and CEO, said in a release. “[It] opens up the opportunity for us to experiment with other types of organic, sustainable plant bases. We’re excited to begin this new chapter.”

Darcey Howard, the brand’s global marketing director, told NOSH the idea behind Everyday Bliss is to reach a broader customer base as private label plant-based offerings have expanded into the freezer aisle. Certain ingredient choices were made for the product to hit a lower price point; for example, the coconut base is sweetened with organic fair trade sugar rather than agave, which is used in the core line. As a result, the texture is lighter — inspired by a plant-based soft serve the company offers in foodservice — and the flavor is more familiar to consumers. Additionally, the packaging uses a “simple and approachable” color palette to reach more consumers, Howard noted.

Everyday Bliss is sold in four flavors: Caramel Macchiato, Salty Peanut Butter Chip, Salted Caramel Chocolate Chip and Vanilla Brownie Swirl. Each retails for $5.49, while the original Coconut Bliss line is $6.99. Everyday Bliss debuted this week in Stop-n-Shop, Albertsons East region and Safeway’s Southwest region; the brand’s original products are sold in 80,000 U.S. stores as well as in Canada, Australia and South America. Howard noted that the majority of the brand’s future growth will continue within the natural channel, but the company will also seek a greater presence in food service. Still, the freezer case has room for more innovation.

“Who knows what the next plant-based trend will be, but the Everyday Bliss line gives us the opportunity to experiment,” Howard said.

CBD & Hemp Update: FDA Commissioner Says Agency Can’t Ban Products

After being appointed commissioner of the Food and Drug Administration (FDA) in December, Stephen Hahn spoke publicly about hemp and CBD for the first time during a presentation Wednesday at the National Association of State Departments of Agriculture (NASDA) Winter Policy Conference in Arlington, Virginia. Hahn said that the agency can’t block CBD products — and that consumers clearly want them.

“People are using these products,” Hahn told the audience. “We’re not going to be able to say you can’t use these products. It’s a fool’s game to try to even approach that.”

Commissioner Hahn noted the FDA acknowledges potential “value” in CBD products but wants to provide consumers with the most accurate information as the market grows.

Also this week, the United States Department of Agriculture (USDA) updated its hemp guidance to temporarily remove the requirement that hemp testing labs register with the Drug Enforcement Agency (DEA.) That stipulation was part of the USDA’s interim final rule published in October, after which industry advocates noted that that DEA involvement would delay the market’s growth. Indeed, the USDA has since received complaints from state governments, farmers and hemp businesses.

“We now better understand how the limited number of DEA-registered labs will hinder testing,” the statement notes. “And [we] better understand the associated costs with disposing of product that contains over 0.3% THC could make entering the hemp market too risky.”

Moving forward, hemp testing can be conducted by labs that are not yet DEA-approved until the final rule is published, or Oct. 31, 2021, whichever comes first, the statement notes. This should provide more time for labs to submit applications, which the DEA will evaluate in accordance with the Controlled Substances Act.

Women on Boards Project Partners with PE, CPG Companies

Nonprofit organization Women on Boards Project (WOB) announced yesterday a partnership with renowned private equity (PE) firms and 20 CPG companies — boosting its mission of improving diversity and inclusion on boards of directors.

New PE partnerships include VMG Partners (also co-founder of the WOB Project), L Catterton, Swander Pace Capital, Alliance Consumer Growth, TSG Consumer Partners, Encore Consumer Capital and CircleUp. In CPG, WOB has brought on food brands Urban Remedy, Simple Mills and Velocity Snack Brands. Every six months, the nonprofit will assist a new brand cohort in forming diverse boards of directors. To do that, the WOB Project established a network of 14,000 women in conjunction with inclusivity-focused talent site theBoardlist.

“Women currently drive 70-80% of all consumer purchasing,” Cassie Nielsen, VP of talent at VMG Partners, said in a release. “Without immediately addressing diversity and inclusion in our boards and leadership, our companies and industries will not meet the needs of our consumers and drive the innovation and fact-based decision making needed to drive growth and profitability in this evolving marketplace.”

The effort has received an “outpouring of support” so far, said Sheryl O’Loughlin, the WOB Project’s co-founder and co-chair (former CEO of REBBL and Clif Bar and co-founder of Plum Organics). Other board members include Alex Hanifin, VP of marketing for better-for-you chip brand The Good Crisp Company; Kara Cissell-Roell, general partner at VMG Partners; and Mita Mallick, Unilever’s head of diversity and cross cultural marketing.

B&G Foods: Q4 and Full 2019 Results, Cauliflower Innovations

After last week’s announcement of its plans to acquire frozen vegetable brand Farmwise, food company B&G this week reported its fourth quarter and full 2019 earnings. The company, which owns frozen vegetable brand Green Giant, saw net sales increase 2.6% year-over-year to reach $470.2 million during the quarter and $1.7 billion during 2019. Net income was $10.3 million and $76.4 million for the quarter and full year, respectively, with a $25.2 million boost coming from its acquisition of flour brand Clabber Girl in May.

During a call with investors, B&G president and CEO Ken Romanzi said more vegetable-fueled innovations will power the company’s future, and that its biggest brand, Green Giant, will “lead the charge again in 2020.” Notably, B&G expects $20 million in new sales via veggie-based innovations from Green Giant, which include Cauliflower Hash Browns, Cauliflower Crust Pizza, Cauliflower Gnocchi and Cauliflower Breadsticks. Additionally, after witnessing “tremendous success” from frozen Green Giant Riced Veggies, now an $18 million business, the brand will launch a shelf-stable Riced Veggie line, he said. Though a $3 billion category, shelf-stable rice sees “little innovation,” Romanzi noted, but these legume and veggie-based offerings contain less carbohydrates and more protein than traditional rice.

B&G’s second largest banner, Mexican-inspired brand Ortega will receive a touch of cauliflower as well. Ortega, bought by B&G in 2003 will launch a new line of Cauliflower Taco Shells and Cauliflower Tortillas, each made with over 25% cauliflower. The brand will also release a line of street taco-inspired sauces.

Additional growth is expected from expanding distribution for premium brand McCann’s Irish Oatmeal, which saw consumption grow 6.5% in Q4.

Beyond Meat: Q4 and Full 2019 Earnings, Goldman Resigns

Yesterday plant-based brand Beyond Meat announced its fourth quarter and full 2019 results, with CEO Ethan Brown noting the company missed its quarterly expectations but exceeded 2019 expectations overall.

“Performance reflects rapidly increasing awareness among consumers around the benefits of plant-based meats,” Brown said during an investor call.

In the fourth quarter, net revenues increased 212% year-over-year to $98.5 million, bringing net revenues to $298 million for 2019, a 239% year-over-year increase. In U.S. retail, the brand generated velocity growth of 106% and grew 26 times faster than competitors in the conventional multi-outlet (MULO) channel for the 52-week period ending December 29, 2019, according to data firm SPINS. Beyond Meat’s products are sold at approximately 77,000 retail and foodservice locations, including Walmart and Whole Foods Market.

“We’re growing extremely fast within retail from a velocity perspective,” Brown said.

Additionally, Starbucks will debut a breakfast sandwich using Beyond Sausage in Canada next week, while Canadian coffee chain Tim Horton’s recently removed a similar product from its menu. But Beyond Meat has boosted breakfast sales at Dunkin Donuts, and is further working with KFC to roll out Beyond Fried Chicken nationally.

Beyond Meat executive chairman Seth Goldman also announced his resignation during the call. In November, Goldman left beverage company Honest Tea to focus on Beyond Meat, but noted the company is in good hands.

“This is just a matter of me having such confidence in the team,” Goldman said. “Frankly 18 months ago, we didn’t have the caliber of leadership we have to support Ethan and now we do — I’m absolutely going to continue to be engaged.”

Although Beyond Meat and rival Impossible Foods often dominate plant-based headlines, other smaller entrants and big CPG companies are seeking a bite: just this week global food and agriculture company Cargill announced plans to launch its own private-label plant-based patties and ground meat in April.

CBD skincare for beginners – Leafly

  Share

This article is brought to you by Populum, a leading provider of CBD supplements, skincare, and pet products made from US grown hemp.


Thinking of using CBD skincare for beauty, acne, and other common skin conditions? Here’s what you need to know.

CBD is everywhere, even the cosmetics aisle. As with any skincare innovation—like peptides or retinol—it can be hard to know where to start. Fortunately, hemp-derived CBD skincare products can be easy to use.

Adding another step to your skincare routine can seem complicated, whether you’re a skincare aficionado with an intricate system or a complete newbie with no idea where to start. Here’s where to start.

What is CBD?

full-spectrum hemp cbd oil, Cannabidiol Oil, Full-Spectrum Hemp CBD Oil, cbd skincare products

(Courtesy of Populum)

CBD is short for cannabidiol, and it’s one of many compounds, called cannabinoids, found in cannabis plants, which includes hemp. These compounds interact with your endocannabinoid system to produce a variety of effects.

Unlike THC – which is associated with the “high” people get from consuming cannabis – CBD isn’t intoxicating. And while CBD is not in all hemp oil, it’s prevalent in many strains of legal-to-cultivate hemp, so it’s the most common cannabinoid you’ll see on store shelves or available for sale online.

What science says about CBD skincare

full-spectrum hemp cbd oil, Cannabidiol Oil, Full-Spectrum Hemp CBD Oil, cbd skincare products

(Courtesy of Populum)

We’re still discovering everything CBD can do, but research suggests it may keep various bodily systems at an even keel, including our skin—which may have an endocannabinoid system of its own, according to 2009 analysis published in Trends in Pharmacological Sciences.

While there are still many more studies that need to be conducted, so far, science has revealed the following about CBD and skin:

Acne

A pesky problem that many people might try to combat with CBD skincare is acne, the cause of which is largely hormonal. While hormones are hard to predict and control, CBD can be helpful as an inflammation fighter that assists with redness and swelling.

A 2014 study found that CBD did, in fact, “help normalize a pro-acne agent” and “inhibit the unwanted growth of sebocytes.” In more common language, it helps your skin keep calm and carry on.

Inflammation

Perhaps the most promising possible use of CBD is CBD as an anti-inflammatory agent. Since many skincare issues are rooted in inflammation, finding products that help with topical inflammation could be vital to maintaining healthy skin.

One study examined the use of CBD for inflammation under and over the skin, including the use of CBD for conditions like arthritis. Featured in Nature Reviews Immunology , the study found that applying sufficiently bioavailable amounts of transdermal CBD can help with inflammation that we can’t see.

full-spectrum hemp cbd oil, Cannabidiol Oil, Full-Spectrum Hemp CBD Oil, cbd skincare products

(Courtesy of Populum)

Itching

An analysis published in the Journal of the American Academy of Dermatology speculated that CBD could work through nerve endings to block itching, citing a 2005 study of hemodialysis patients.

A 2006 study in German journal Der Hautarzt showed that 86.4% of a test group experienced a reduction in pruritus, the sensation of uncomfortable itch, when using CBD to address chronic, treatment-resistant itching.

Just remember: because skin itch is caused by something mechanical (related to the body’s processes), thermal (heat-based), or chemical (contact-based), it’s essential to find the cause of the itch before you try anything or cause further irritation.

Scarring

Scars are made of damaged skin tissue resulting from injury, surgery, or acne. Topicals like creams and scrubs are often used to soothe the skin or help with cell regeneration throughout the healing process.

A 2019 study in La Clinica Teraputica found that patients with inflammatory scarring saw significant improvement of symptoms when a CBD ointment was applied to their skin, including more satisfactory scar paraments – indicating that CBD’s anti-proliferative and anti-inflammatory effects can help scarring caused by inflammation.

As for other types of scarring, the jury is still out.

Elasticity

As the epidermis thins, skin loses its elasticity, leaving many wishing they could help their skin snap back into shape.

The La Clinica Teraputica study that found so much rich information about scarring also found increased elasticity in the skin of subjects who used a topical CBD treatment. However, it’s unclear whether that was because of the CBD itself or other ingredients in the ointment.

What we do know about CBD skincare and elasticity is that you should follow always follow best practices. Don’t skimp on your skincare products on the delicate skin under your eyes and on your neck. Pick cannabinoid-rich products with botanicals that work naturally with the skin, and apply once or twice a day to keep the skin in these vulnerable areas supple and hydrated.

Tips for choosing CBD skincare products

full-spectrum hemp cbd oil, Cannabidiol Oil, Full-Spectrum Hemp CBD Oil, cbd skincare products

(Courtesy of Populum)

You can achieve your CBD skincare dreams by researching the different formats of CBD skincare products available on today’s market and matching them with your unique needs. Here are a few things to consider when selecting your perfect CBD skincare product.

1. Learn exactly what’s available.

CBD skincare has come far in just the last few months. Make sure you are aware of all the latest product formats, like topicals, lip butters, and day vs. night formulas to target your issues.

2. Make sure to account for differences in CBD products for face and body.

The skin on our bodies often tolerates heavier formulas than our faces will, with less of a chance for breakouts. Try a serum or CBD face oil for the face and keep balms and lotions for the neck down.

3. Get ready to expand your skincare routine.

Skincare gurus know that there are no miracle products out there. A CBD skincare routine should include consistent application if you want to see results. Carve out the extra few minutes each day and chalk it up to self-care.

Finding the right CBD skincare for you

full-spectrum hemp cbd oil, Cannabidiol Oil, Full-Spectrum Hemp CBD Oil, cbd skincare products

(Courtesy of Populum)

While research is showing a lot of promise for CBD skin treatments, at least one study advises caution when picking out a product: A study published in JAMA, summarized by a medically-reviewed Healthline summary, found that a whopping 26 percent of CBD skincare products contained less CBD than advertised. But that’s not the case with Populum.

“Right now, third-party lab testing is the thing that separates the good from the bad when it comes to CBD skincare products,” says Gunhee Park, the Populum CEO. He also points out that the FDA doesn’t have a list of tests required for cosmetic products – which can make choosing the perfect product more difficult than it needs to be.

So, when Populum decided to make a face oil, they used the same tests they use on their tinctures, triple-testing for heavy metals, pesticides, residual solvents, microbials, and mycotoxins, in addition to cannabinoid potency.

“Consumers must be especially vigilant when choosing skincare products,” says Park. “Just like things you put into your body, it’s important to know the ingredients you’re putting on your skin.”

Now, you’re primed and ready to experience CBD skincare for yourself.

Start with Populum’s Lavender + CBD Face Oil at populum.com.

  Share

[/vc_row]

THC cap for med pot filed in Florida Senate – Tampa Bay Times

TALLAHASSEE — In a last-ditch effort at the tail end of the legislative session, the chamber most likely to oppose a cap on THC has taken up the issue.

After weeks of rumors that the Florida House was pushing an amendment that would put a cap on the amount of THC in all medical marijuana at 10% potency, the proposal was finally filed Friday afternoon in the Senate.

THC is the main psychoactive compound in marijuana, and can come in the form of whole-flower marijuana, tinctures, oils, vaporizers and edibles.

Sen. Gayle Harrell, R-Stuart, filed the amendment to a larger health care package. The Senate Rules committee, the bill’s last stop, will take up the amendment Monday afternoon.

Current law places a limit on the amount of THC in edible products only, which may only contain 10 mg of THC per serving and 200 mg in total. The levels are much higher than what most patients would normally consume, according to industry experts.

The amendment caps THC at 10% potency for patients under 21 years old, with exceptions for those who are terminally ill and for patients whose doctors can make a case for medicine with more THC.

Harrell said she is concerned about the amount of THC young people have access to, and that marijuana could negatively affect the developing brain.

“I have been very concerned about this,” she said. “You’re seeing increasing percentages of THC in marijuana. This is not your granddaddy’s marijuana from the ‘60s.”

The idea of capping THC first came up during the 2019 Legislative session with a House bill that would have capped THC at 10% potency in smokable medical marijuana, or “flower.” That bill also would have prohibited doctors from certifying patients under 18 for full-strength marijuana, give free medical-marijuana identification cards for veterans and provide $350,000 to the Department of Health to implement the bill.

The bill, put forward by Rep. Ray Rodrigues, R-Estero, cited research indicating that high-potency marijuana is associated with earlier onset of psychosis and the development of schizophrenia in marijuana users.

The Swedish study he cited was based on patients who had experienced at least one psychotic episode in their lives and then self-reported their previous marijuana usage to researchers.

Despite support from Speaker Rep. José Oliva, R-Miami Lakes, the idea never progressed in the House.

Sen. Jeff Brandes, who held a press conference earlier this week urging the House to not push a THC cap, said that he believed the more moderate Senate would “hold the line” on the issue.

Friday, Brandes, R-St. Petersburg, expressed his disappointment and said the Senate should focus on “solving real problems.”

“Physicians understand much better than the Legislature what’s best for their patient,” he told the Herald/Times in a text message. “Let’s let doctors weigh benefits and risks for their patients.”

Harrell said she and Brandes have “very different views” on the issue.

“You can have people who don’t want any caps on marijuana,” she said. “They want free pot everywhere. It’s not unanimous support for any regulation whatsoever. But this is a reasonable safety precaution.”

Senate President Bill Galvano, R-Bradenton, indicated earlier this session that he was open to considering a THC cap.

The industry perspective

Opponents to the amendment say the mandate will be a burden on medical marijuana providers, force prices up for patients and drive patients to the black market to self medicate with higher-THC marijuana.

In 2016, advocates in Colorado pushed to limit THC to 16% via referendum but ultimately withdrew the plan.

A proposal in Washington state to cap cannabis at 10% THC is currently stalled in committee, with lawmakers indicating last week that they will prevent the measure from moving forward.

In Alaska, a proposal to cap marijuana product potency at 76% THC was also voted down.

Nick Hansen, MedMen’s vice president of government affairs, said the proposal is “unconstitutional” and goes against what Florida voters wanted when they voted to legalize medical marijuana in 2016.

“It puts the Legislature in between patients and their doctors,” he said. “It limits the ability for patient to get the care they need.”

He added that every time there is a change in how the marijuana businesses in Florida have to operate, it takes time, research and money to develop new formulas. For instance, when smokable “flower” marijuana became legal, the industry scrambled to grow more flower and keep up with high demand.

“Every time you change formulas it’s a complex process,” he said. “These are not just things where you can flip the switch and go the other way … this is what happens when people who are not doctors start making decisions .

Barry Gordon, a Venice-based medical marijuana doctor, said the amendment targets the “most vulnerable” population, and that physicians will find the concept to be “absurd.” Gordon treats about 30 pediatric patients, and says they all have varying needs when it comes to THC levels. But that is a decision a doctor makes with a patient or parent, and Tallahassee need not be involved, he said.

“Every doctor that practices medical cannabis responsibly discusses brain development with the parent,” said Gordon, who operates the largest cannabis clinic in the state “This gets in the way of the doctor-patient relationship.”

Michelle Weiner, a South Florida pain doctor who prefers to prescribe her patients medical marijuana instead of opioids, said she disagrees with capping THC, but that she tends not to recommended THC for patients under 21, anyway.

“The research states that you shouldn’t give THC to a developing brain, so there is evidence on that,” she said. “In general, we try not to give THC to anyone under 21 or 22. But there shouldn’t be a blanket [bill]. A THC cap is ridiculous, under 21 or not.”

AZ Lawmaker: Marijuana Makes People “Paranoid Schizophrenic and Act out Violently” – AZmarijuana.com

Arizona THC

House Concurrent Resolution 2045, introduced by Arizona House Speaker Rusty Bowers, seeks to limit medical marijuana to 2% THC and require cigarette-like warning labels be added on all medical marijuana products.

HCR 2045 would also require that the Arizona Department of Health Services (ADHS) research unsubstantiated links between cannabis use, schizophrenia and violence, Phoenix New Times reported.

“Not everybody’s going to become paranoid schizophrenic and act out violently, but a lot of people are,” Bowers claimed.

Bowers isn’t an expert on cannabis by any means–he just happened to have read a Reefer Madness-touting book recently, and then decided to create a new bill (HCR 2045) based off his new medical “discoveries” about cannabis.

“This bill would essentially end the medical marijuana program in Arizona as we know it,” said Dr. William Troutt, a local naturopath. “The only cannabis varieties below 2 percent THC in the dispensary are CBD varieties.”

The highly irrational bill would drastically upend Arizona medical marijuana patients’ lives because patients would no longer have access to potent-enough medical marijuana flowers, concentrates, edibles, tinctures and topicals.

However, Sam Richard, Executive Director of the Arizona Dispensaries Association, recently said that Bowers agreed to remove the 2% THC limit. But only time will tell if this is true, a rumor or a tactic to elude the Arizona medical marijuana community.

“Rusty Bowers has been a very hardhearted legislator when it comes to caring about the way that marijuana has improved the lives of people,” said Mikel Weisser from the Arizona chapter of the National Organization for the Reform of Marijuana Laws (NORML).

If the bill passes through the House and Senate it could be on Arizona voters’ ballots this November.

Contact your local representative to convey your opinion on this cannabis issue.

Success!